Cladribine

Cladribine is a drug commonly used to treat hairy cell leukemia . Its brand name is Leustatin, and it is commonly referred to as 2CDA.A purine analog, it is a synthetic antineoplastic agent with immunosuppressive effects. Chemically, it mimics the nucleoside adenosine and thus inhibits the enzyme adenosine deaminase, which interferes with the cell's ability to process DNA. It is easily destroyed by normal cells in the body except for blood cells, with the result that it produces relatively few side effects and results in very little non-target cell loss. (From the Wikpedia article Cladribine.)

Download PDF containing detailed information.

Recent Publications on Cladribine:
Cladribine treatment in two-hour intravenous infusion for previously-treated low grade B-cell lymphoma: a pilot study. Cladribine is approved to be used in 24-hour continuous infusion for the...	13th November, 2009	Division of Medical Oncology, Hematology and Infectious Disease,	J Clin Exp Hematop. 2009 Nov;49(2):69-75.
New oral drugs for multiple sclerosis. Disease-modifying treatments are now available in relapsing-remitting and...	13th November, 2009	Centro Sclerosi Multipla, Azienda Ospedaliera S. Camillo-Forlanini, Rome,	Neurol Sci. 2009 Oct;30 Suppl 2:S179-83. DOI Direct Link
Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. BACKGROUND:: The prognosis after recurrence of pediatric acute myeloid...	4th November, 2009	Department of Oncology, St. Jude Children's Research Hospital, Memphis,	Cancer. 2009 Nov 2. DOI Direct Link
Approach to the patient after relapse of hairy cell leukemia. The current hairy cell leukemia (HCL) treatment is excellent, but evidence...	21st October, 2009	Laboratory of Molecular Biology, National Cancer Institute, National	Leuk Lymphoma. 2009 Oct;50 Suppl 1:32-7.
Long-term follow-up studies in hairy cell leukemia. Enormous progress has been made in the management of patients with hairy...	21st October, 2009	Department of Medicine, The Ohio State University, Columbus, OH, USA.	Leuk Lymphoma. 2009 Oct;50 Suppl 1:23-6.
→View more research publications.

Press Releases About Cladribine:
Merck Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States	30th September, 2009		GENEVA, September 30 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the submission of a New Drug Application (NDA) to the US Food and Drug Administration
EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States	30th September, 2009	EMD Serono, Inc.	-- The ONWARD (Oral Cladribine Added ON To Interferon beta-1a in Patients With Active Relapsing Disease) study: a Phase II placebo-controlled trial designed primarily to evaluate
New Data From CLARITY Study on Disease Activity in MS Patients who Received Cladribine Tablets Presented at 25th ECTRIMS Congress	11th September, 2009		DÜSSELDORF, Germany and GENEVA, September 11 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced new data from a post-hoc analysis of the two-year (96-week) placebo
Merck Serono Submits Application for Cladribine Tablets as Multiple Sclerosis Therapy in Europe	23rd July, 2009		GENEVA, Switzerland, July 23 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the submission of a marketing authorization application (MAA) to the European
Merck Serono Launches RebiSmart(TM), First Electronic Injection Device for Delivery of Multiple Sclerosis Treatment Rebif(R)	24th June, 2009		GENEVA, June 24 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the launch of the innovative individually adjustable electronic injection device RebiSmart

BioNews Results for Cladribine:
Merck Submits Application for Cladribine Tablets as a Multiple Sclerosis Therapy in the United States	Bionity.com:  Oct 6 2009 5:11AM Matching: cladribine
EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Ther	PR Newswire via Yahoo!:  Sep 30 2009 4:17PM Matching: cladribine

Cladribine Patents:
US Patent No.	Title
7579503	BIS (thio-hydrazide amide) salts for treatment of cancers
7589190	Potent LNA oligonucleotides for the inhibition of HIF-1A expression
7591844	Medical devices, drug coatings and methods for maintaining the drug coatings thereon
7592016	Methods for preparing and using implantable substance delivery devices
7592342	Quinoxaline derivatives as PI3 kinase inhibitors
→View more patents.

BioPortfolio Ltd. offers e-mail and postal lists for Cladribine scientists - we have details of around 115 individuals working on Cladribine .